Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

Achieved revenue of $704 million and net income of $203 million highlighting the first profitable quarter as a commercial stage company Reiterating full year...

Related Keywords

South Korea ,Australia ,South Africa ,Japan ,Bangladesh ,New Zealand ,Thailand ,India ,United Kingdom ,Singapore ,United Arab Emirates ,Canada ,Switzerland ,Great Britain ,Stanleyc Erck ,Alison Chartan ,Instagram ,Linkedin ,Twitter ,National Institute Of Allergy ,Prnewswire Novavax Inc ,Vaccine Clinical Development ,Advisory Committee ,Takeda Pharmaceutical Company ,Coalition For Epidemic Preparedness Innovations ,Nasdaq ,European Union ,Serum Institute ,Facebook ,Novavax Inc ,Clinical Development ,European Commission ,World Health Organization ,Exchange Commission ,Novavax Influenza Program ,Serum Institute Of India Pvt ,Products Advisory Committee ,Australia Thailand ,Influenza Combination ,Chief Executive Officer ,Worldwide Authorizations ,Booster Vaccination ,Adult Population Aged ,Takeda Pharmaceutical Company Limited ,Related Biological Products Advisory Committee ,Regulatory Pathway ,Children Aged ,Vaccine Candidate Clinical ,Kingdom Phase ,South Africa Phase ,National Institute ,Three Months Ended March ,Epidemic Preparedness ,World Health ,Financial Condition ,Novavax Annual Report ,Novavax ,Nc ,